+34 9340006100 -ext. 437807-info@nanbiosis.com


Unit 2 of NANBIOSIS participates in the FoodSmartPhone project of Marie Sklodowska Curie.

The Nb4D group of CSIC, coordinator of Unit 2 of NANBIOSIS led by Pilar Marco has joined the consortium for the FoodSmartPhone project funded by the Marie Sklodowska Curie Research Program. The Marie Sklodowska-Curie Actions (MSCA) support training in research and professional development aimed at innovation skills.

The objective of the project is to develop a smartphone-based diagnostic and detection tool for simplified quick pre-selection of food quality and safety parameters. This is because food safety and quality tests are currently inefficient, expensive and ineffective and can not guarantee food safety for all consumers or prevent possible incidents of food fraud.

FoodSmartPhone offers an opportunity for a doctorate that covers all aspects of smartphone-based detection tools, as well as a wealth of scientific knowledge as well as innovation and transfer.

The Nb4D group will act as leader of work package For more information 1 which aims to develop new concepts of ligand binding assay. The group will host two ESRs (Early Stage Researchers) and will also organize training events and an advanced PhD course for the production of haptens and bioreceptors.

For more information

Unit 2 of NANBIOSIS participates in the FoodSmartPhone project of Marie Sklodowska Curie.
Read More

The CIBER-BBN, partner of NANBIOSIS together with CCMIJU, incorporates two new research groups

The CIBER-BBN, partner of NANBIOSIS together with CCMIJU, has incorporated two new groups. One of them, led by José Miguel López-Higuera, is the Photonics Engineering Group of the University of Cantabria. The other is the Nanotechnology and Apoptosis Group of the Materials Science Institute of Aragon (CSIC-University of Zaragoza) led by Jesús Martínez de la Fuente. The incorporation of these groups has become official in the Governing Council of the CIBER celebrated on December, 1st

The CIBER-BBN currently has 47 research groups, selected on the basis of their scientific excellence, working mainly within three scientific programs: 1. Bioengineering and Medical Imaging, 2. Advanced Biomaterials and Therapies and 3. Nanomedicine. The activities of the center is oriented both to the development of prevention, diagnosis and monitoring systems and to the development of technologies related to specific therapies such as regenerative medicine and nanotherapies.

Jesús Martínez de la Fuente and the NAP group

The Group of Nanotechnology and Apoptosis (NAP) focuses its research on the development of general methodologies for the functionalization of nanoparticles and surfaces always looking for biotechnological applications.

Jesús Martínez de la Fuente is the author of about 150 articles in scientific journals of the highest level and inventor of 6 international patents, all licensed. He is an associate member of the Center for Cell Engineering of the University of Glasgow and of the Institute of Applied Sciences and Intelligent Systems of the Italian CNR in Naples and professor at the National Center for Translational Medicine (Shanghai Jiao Tong University, China). He is also co-founder and scientific advisor of the company NANOIMMUNOTECH S.L.

José Miguel López-Higuera and the Group of Photonic Engineering

The Photonics Engineering Group focuses its work on fiber optic sensor systems and instrumentation.
Prof. López-Higuera is a Fellow of the OSA, USA; Fellow of SPIE, USA, and member of the Royal Academy of Medicine of Cantabria. He is the Director of the International School of Light Sciences and Technologies that develops the fourth week of June of each year to the highest scientific and technological level in the world. He has made more than 600 academic and 17 industrial publications (patents). He has co-founded three technology-based companies.

The CIBER-BBN, partner of NANBIOSIS together with CCMIJU, incorporates two new research groups
Read More

The Journal “Diario Médico” awards the project “Liver on a chip” participated by researchers of U8 of NANBIOSIS

The 15th edition of  “Best Ideas 2016” by Diario Médico, has awarded the “Liver on a Chip” project, coordinated by Rosa Villa, Scientific Coordinator of Unit 8 of NANBIOSIS.

“Liver on a chip” is a microfluidic camera that simulates hepatic microcirculation and will serve as a tool for in vitro studies and diagnostics of cell function, pharmacology, toxicity and personalized medicine. The device could be applicable to any other biomedical research in That the vascular system has relevance (liver, kidney, cardiovascular and others).

This project was already recognized last July with the second prize of the category of innovation in research results of the second Contest of Innovation in Health of the Vall d’Hebron Research Institute (VHIR)

The Journal “Diario Médico” awards the project "Liver on a chip" participated by researchers of U8 of NANBIOSIS
Read More

NANBIOSIS at the CIBER-BBN X Annual Conference and 1st meeting of the NANBIOSIS SAB

The X Annual Conference of CIBER-BBN, held in Sevilla last 28 and 29 of November, dedicated a Session to NANBIOSIS on Monday afternoon, to which attended national and international representatives of industry and academia users of NANBIOSIS, representatives of EATRIS and members of the Scientific and Technical Advisory Committee of NANBIOSIS, as well as the CIBER-BBN and the CCMIJU researchers.

Jaume Veciana, Scientific of NANBIOSIS and Ángela Fernández Curto, Assistant Deputy Director General for Planning of Scientific and Technological Infrastructures of Spanish Goverment presented the Unique Technical Scientific Infrastructure (ICTS) of CIBER-BBN and JUMISC for the production and characterization of biomaterials, nanomaterials and devices until their preclinical validation. Among the biomedical applications that frame the activity of NANBIOSIS are diagnostic, regenerative medicine and drug administration, as well as its next Cascade Characterization Service for the preclinical evaluation of nanomedicines.

The project “PRONANBIOSIS” funded by the Spanish Ministry of Economy and Competitiveness with a “Network of Excellence” to consolidate the unified management model of NANBIOSIS, to boost its internationalization and strategic positioning as well as to promote a complete nanomaterials characterization cascade service, was also presented and some of the” success stories “of the ICTS where explained.

Since its launch in July 2015, NANBIOSIS has received more than 250 access requests, with an average participation of about 50 competitive projects per year and annual revenues for its services of between 1 and 2 million euros. Among its users, there are more than 100 companies, especially pharmaceutical laboratories, and more than 300 research groups. In addition, its 27 units are involved in several national and European projects, such as BERENICE (nanoformulation of the active to combat Chagas disease), DRIVE (development of a device with pancreatic cells for diabetes treatment) and several public- Former INNPACTO (PHYTEC -Development of bioactive coated medical products for bone regeneration- and VITILIGO -Development of a new advanced therapy drug for the treatment of Vitiligo-), several projects Challenges Collaboration, or the Network of Excellence Pronanbiosis for the promotion and Consolidation of the ICTS, among others.

At the Conference, the NANBIOSIS Scientific Advisory Committee convened to discuss the key actions of its next Strategic Plan, such as the new Cascade Characterization Service for the preclinical evaluation of nanomedicines.

NANBIOSIS at the CIBER-BBN X Annual Conference and 1st meeting of the NANBIOSIS SAB
Read More

“It is necessary to increase our relationship with European research groups” by José Luis Pedraz – U10 of NANBIOSIS

Last Sunday, November 27, the Newspaper of Álava published a special supplement with the title “ALAVA 2020”. It contained an article by José Luis Pedraz (Scientific Director of Unit 10 of NANBIOSIS)

According to Dr. Pedraz, group leader of the CIBER-BBN NANOBIOCEL group, in the next future, important challenges with new technologies will allow a considerable advance in the treatment of diseases of genetic origins. In this context, it is crucial to increase the number of international contacts in order to be able to access new infrastructures more competitively. The opening of new lines of research and the creation of new research infrastructure through consortiums such as CIBER-BBN or the Unique Scientific and Technologic Infrastructure (ICTS) NANBIOSIS generate an advantageous situation to attract new investments and create new companies. Pedraz continues explaining that we must increase our relations with European research groups in order to build consortia with which participate in for European research calls.

The NANOBIOCEL Group, coordinator of Unit 10 of NANBIOSIS, currently participates in two European consortiums (DRIVE Project) and (BERENICE Project) .

"It is necessary to increase our relationship with European research groups" by José Luis Pedraz - U10 of NANBIOSIS
Read More

X Annual Conference of CIBER-BBN

The next days 28 and 29 of November the X Annual Conference of CIBER-BBN will be held in Seville.

Within this Conference, 3 thematic forums have been organized for clinical translation, where doctors will present the current challenges of diagnosis and treatment in certain diseases and a debate will open between doctors and
researchers to develop research lines and projects aimed at solving those needs.

Taking advantage of the presence of clinical professionals, NANBIOSIS has organized a session dedicated to presenting itself as “Unique technological scientific infrastructure” (ICTS in Spanish) as well as the nodes that are
part of it. Some cases of success and results will be also presented in order to ´make known the services and advantages offered by NANBIOSIS and facilitate the translation of the research developed in the ICTS.

This session will be attended by Ángela Fernández Curto, Assistant Deputy Director General for Planning of Scientific and Technological Infrastructures MINECO who will explain what is and “ICTS”, Jaume Veciana and Jesús Izco, Scientific Director and Coordinator of NANBIOSIS respectively who shall give some general explanations about NANBIOSIS and what has been done in this year of progress since its recognition as ICTS by MINECO,

Finally, The broader part of the session will be led by the following Coordinators or Scientific Directors of the NANBIOSIS Platforms, who will make a brief presentation of each and will present some cases of success:

Also at the Conference, the NANBIOSIS Scientific Advisory Committee will meet to discuss the key actions of its next Strategic Plan, such as the new Cascade Characterization Service for the preclinical evaluation of nanomedicines.

Read More

Award to research with micronanotechnology.

The Royal Spanish Academy of Engineering has awarded a medal to Víctor Sebastián Cabeza, researcher of the group “Nanostructured Films and Particles”, which coordinates Unit 9 of NANBIOSIS.

The prize has been awarded in recognition of his work in designing a wide variety of micro-reactors to produce nanomaterials in a controlled and successful manner, reducing time and costs, with applications in Biomedicine, catalysis or energy processes.

Dr Víctor Sebastián also received the prestigious Fulbright scholarship in 2009 to carry out a postdoctoral research at the Massachusetts Institute of Technology (MIT) on nanomaterials and its development in microfluidics and in 2014 the European Academy awarded him the Burgen Scholarship Award recognizing him as one of the young researchers with greater scientific projection. Victor works in the field of micronanotechnology for its application in Biomedicine, Catalysis or energy processes. In particular, it has designed a large variety of micro-reactors with sub-millimeter dimensions that allow very precise control of the reaction conditions of the chemical processes that take place in them.

Dr Sebastian is an active member of Unit 9 of Nanobiosis, where he develops microfluidic system for biomedicine that allow a highly precise synthesis of nanomaterials.

Award to research with micronanotechnology.
Read More

Successful meeting on Biomedicine between the University of Turin and NANBIOSIS/CIBER-BBN

Last November 8th, 2016 took place in Barcelona, in the Residence of Researchers of CSIC, a meeting of Italian-Spanish scientists, the first Investigators B2B Forum organized by NANBIOSIS. The meeting reached its objective of bringing together the interests of researchers from University of Turin and NANBIOSIS/CIBER-BBN on biomaterials and nanomedicine.

Nine groups from L’Università di Torino together with sixteen groups from CIBER-BBN and CCMIJU (partners of NANBIOSIS), got together to explain through short presentations of ten minutes, those lines of their work aimed at finding synergies and potential collaborations. In the afternoon, the groups had the opportunity to discuss in more detail, during bilateral interviews coordinated by NANBIOSIS, those aspects that had attracted their attention, as well as, in some cases, to draw potential collaborations.

Topics as preclinical validation of nanomedicines, animal models, custom peptide synthesis, carbon nanotubes and graphene for biomedicine, micronanotecnology, drug microencapsulation, nanoestuctured liquid characterizacion, surface microanalysis of biomaterials, pharmacodynamics, preclinical in vivo MRI and MRSI, tissues and biomaterials MRI, nanoparticles for drug delivery, nanoestructuring soft materials or customized molecular materials for biomedical applications, among others, were discussed during the 75 B2B meetings celebrated.

All the attendees expressed, at the end of the event, the usefulness of the meetings with this format and their satisfaction at having found possibilities of collaboration thanks to their participation in this forum and encouraged NANBIOSIS to continue this initiative.”


Successful meeting on Biomedicine between the University of Turin and NANBIOSISCIBER-BBN
Read More

Extraordinary doctoral award

Ingrid Cabrera, member of the NANOMOL group that coordinates Unit 6 of NANBIOSIS, has obtained the extraordinary doctoral award from the Universitat Autònoma de Barcelona for her thesis “Nanovesicle-bioactive conjugates to be used as nanomedicines, prepared by a one-step scalable method Using CO₂-expanded solvents“.

This thesis was directed by Jaume Veciana, Scientific Director of NANBIOSIS and Nora Ventosa, Scientific Director of Unit 6 of NANBIOSIS.

The main objectives of the  PhD Thesis of Dr. Ingrid Cabrera were the preparation and study of multifunctional nanovesicle based nanoformulation of alfa-galactosidase for the treatment of Fabry desease as well as of another multifunctional nanovesicle based nanoformulation of epidermal growth factor for the treatment of complex wounds. Both nanoformulations were prepared by a one-step procedure using compressed fluids at U6 of Nanbiosis. This platform also provided many nanoparticles characterization facilities that enabled to obtain important information on the supramolecular organization and characteristics of the produced multifunctional nanovesicles that were key for understanding their biological activities.

Extraordinary doctoral award
Read More

Graphene will revolutionize the world

Elisabet Prats, researcer of the GBIO Group, coordinator of Unit 8 of NANBIOSIS, participated in the  #ImproCiencia dissemination event, held on November 16 in Madrid organized by CIBER. Elisabet presented the Neurographene project as a monologue and explained how they are using graphene for Measure the electrical activity of the brain.

Based on the latest microfabrication technologies, the devices consist of graphene microsensor matrices mounted on flexible polymer substrates that adapt to the surface morphology of the brain.

Each sensor detects tiny changes in the electrical activity around it. Thus, the electrical activity generated by the neurons is detected as a small change in the conductivity of the graphene sensor. These devices are already being used in the study of sleep and epilepsy in animal models. The graphene sensor implanted on the brain surface allows the simultaneous recording of electrical activity in different regions of the cortex.

Also, the technology of flexible graphene sensors can be used in other biomedical applications in which it is necessary to obtain relevant information from the cerebral cortex. “Graphene will revolutionize the world,” said Elisabet Prats.

Graphene will revolutionize the world
Read More